恩华药业 (002262)

Jiangsu Nhwa Pharmaceutical Co.，LTD

ASZ

Tags

MSCI Mid Cap IndexGeneric DrugsChemical PharmaceuticalsSustainable GrowthEmerging Markets IndexSmart HealthcareHigh-Performing StocksShenzhen ConnectSZSE 300 IndexTech 100 IndexPharma & BiotechSZSE Defensive 50 IndexStable Growth IndexSME Board Emerging IndexSZSE Medicine Equal Weight IndexSME 100 Return IndexShenzhen A-Share Pharmaceutical IndexCS High Dividend Yield IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexSHS Technology 100 IndexSZSE 1000 IndexSME Board Equal Weight IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCNI 1000 IndexXingyin Wealth Management Balanced 300 IndexCSSW Silk Road IndexZhongchuang Value IndexCSI 500 Value Stable IndexPrivate PlacementYangtze River Delta Economic ZoneFTSE Russell ConceptShareholding Increase CommitmentInsurance Heavy HoldingsSME Board Composite IndexSZSE Selected IndexTechnology 50 Strategy IndexCS High-end Manufacturing IndexNew IndexEmerging Industries Composite IndexManufacturing IndexSZSE ChiNext 100 IndexSecurities Times Value 100 IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI IndexCSI 1000 IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexJuchao Small-cap IndexCCTV 500 IndexCS Pharmaceutical Innovation IndexChina United Quality Growth IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexSZSE Low Volatility IndexCSI All-share Pharmaceutical IndexCSI Yangtze River Delta IndexSZSE Pharmaceutical 50 IndexSME Board Low Volatility IndexSZSE 300 Equal Weight IndexCSI Pharmaceutical IndexCSI 500 Equal Weight IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightCCB Technology (Yangtze River Delta) IndexPharmaceutical & Health 100 IndexSME Board Performance IndexCSI 700 IndexMid-small Cap IndexCSI 500 IndexCSI 500 IndexPharmaceutical 50 IndexZhongchuang Low Volatility IndexSmall-cap Low Volatility IndexCSI 500 Growth Innovation IndexPharmaceutical 50 Strategy IndexCSI 1000 Growth Innovation IndexSZSE 200 Return IndexSZSE 200 IndexYangtze River 100 IndexZhongchuang 400 IndexCR New Momentum IndexOrient Securities Competition IndexSZSE 500 IndexCSI 500 ESG IndexSuyin Wealth Management Yangtze River Delta IndexCS Yangtze River Delta Index

K-Line Chart

No K-line data available

Company NameJiangsu Nhwa Pharmaceutical Co., Ltd.
Listing Date2008-07-23
Issue Price5.68RMB
Registered Capital101578.658310k RMB
Legal RepresentativeSun Pengsheng
Registered AddressNo. 18 Yangshan Road, Xuzhou Economic and Technological Development Zone, Jiangsu Province, China
IndustryChemical Pharmaceuticals
Main BusinessProduction and sales of central nervous system drug preparations and active pharmaceutical ingredients.
Company ProfileJiangsu Nhwa Pharmaceutical Co., Ltd. was founded in 1978 and listed on the Shenzhen Stock Exchange in 2008 (Stock Code: 002262). It is an integrated pharmaceutical enterprise encompassing research, manufacturing, and trade. The company is a designated national producer of psychotropic drugs, a National High-Tech Enterprise, one of China's Top 100 Pharmaceutical Companies, a National Technology Innovation Demonstration Enterprise, a National Intellectual Property Demonstration Unit, a "20 Years 20 Stars" Star Unit for Pharmaceutical Quality Management, an ISO14000 certified enterprise, one of the first batch of Innovative Enterprises in Jiangsu Province, Vice President Unit of the China Narcotic Drugs Association, and Vice President Unit of the Jiangsu Pharmaceutical Industry Association. The company primarily engages in the production and operation of central nervous system (CNS) drugs, strategically focusing on the CNS drug market. It is dedicated to the development, production, and sales of CNS drugs, specializing in this market segment. Its main product categories include anesthetics, psychotropics, and neurological drugs. Through years of relentless effort in product R&D, production, and services, the company has established a comprehensive portfolio of CNS drug products and a marketing network, striving to become a major domestic manufacturer and distributor of central nervous system drugs.

Stock Details

1. Key Indicators

  • Total Shares(W): 101578.66
  • Circulating A-Shares(W): 88390.85
  • Earnings Per Share(RMB): 1.0900
  • Net Assets Per Share(RMB): 7.9779
  • Operating Revenue(W RMB): 447098.88
  • Total Profit(W RMB): 123355.72
  • Net Profit Attributable to Parent(W RMB): 110604.74
  • Net Profit Growth Rate(%): 8.42
  • Weighted Return on Equity(%): 14.3100
  • Operating Cash Flow Per Share(RMB): 0.8970
  • Undistributed Profit Per Share(RMB): 6.2711
  • Capital Reserve Per Share(RMB): 0.2730

2. Main Business

The main business covers:

  • Pharmaceutical R&D, production, and sales

3. Company Basic Information

  • Company Name: Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Listing Date: 2008-07-23
  • Industry: Pharmaceutical Manufacturing
  • Address: Nhwa Technology Building, No.31 Longhu West Road, Economic and Technological Development Zone, Xuzhou City, Jiangsu Province
  • Website: www.nhwa-group.com
  • Company Profile: The company was established as a joint-stock company through the overall change of the audited net assets of Jiangsu Nhwa Pharmaceutical Group Co., Ltd. as of December 31, 2006. On April 29, 2007, the company was legally registered and approved by the Xuzhou Administration for Industry and Commerce, obtaining the "Business License of Enterprise Legal Person" with registration number 3203002112097. The registered capital was 90 million yuan, with a par value of RMB 1.00 per share, and the legal representative is Sun Pengsheng.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Xuzhou Nhwa Investment Co., Ltd. General Legal Person 32009.63 36.21
2 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1328.84 1.50
3 National Social Security Fund 101 Portfolio Social Security Fund 1242.85 1.41
4 National Social Security Fund 413 Portfolio Social Security Fund 940.18 1.06
5 Penghua Optimal Value Stock Securities Investment Fund Class A Fund 385.01 0.44
6 Southern Medical Healthcare Flexible Allocation Hybrid Securities Investment Fund Class A Fund 285.72 0.32
7 Dacheng Consumption Theme Hybrid Securities Investment Fund Class A Fund 200.07 0.23
8 Dacheng Jingyang Leading Hybrid Securities Investment Fund Class A Fund 135.74 0.15
9 Dacheng Yuanchen Zhaoli Bond Securities Investment Fund Class A Fund 125.96 0.14
10 Dacheng Positive Growth Hybrid Securities Investment Fund Class A Fund 118.92 0.13

5. Concept Sectors

  • Smart Healthcare
  • Generic Drugs
  • Innovative Drugs
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Social Security Fund Heavy Holdings
  • Sustained Growth
  • MSCI Mid Cap
  • SME 100
  • SZSE 300
  • Technology 100
  • SME 300
  • SZSE Innovation
  • Innovation 100

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information